180 related articles for article (PubMed ID: 33243261)
1. Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis.
Han Y; Liu X; Ye H; Tian Y; Ji Z
World J Surg Oncol; 2020 Nov; 18(1):310. PubMed ID: 33243261
[TBL] [Abstract][Full Text] [Related]
2. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
[TBL] [Abstract][Full Text] [Related]
3. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
[TBL] [Abstract][Full Text] [Related]
4. TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.
Kawahara T; Kojima T; Kandori S; Kurobe M; Yoshino T; Kimura T; Nagumo Y; Ishituka R; Mitsuzuka K; Narita S; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Miyazaki J; Nishiyama H
PLoS One; 2019; 14(8):e0220173. PubMed ID: 31369573
[TBL] [Abstract][Full Text] [Related]
5. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.
Ma D; Jiang YZ; Liu XY; Liu YR; Shao ZM
Breast Cancer Res Treat; 2017 Feb; 162(1):39-48. PubMed ID: 28093659
[TBL] [Abstract][Full Text] [Related]
7. A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC).
Roperch JP; Hennion C
BMC Med Genet; 2020 May; 21(1):112. PubMed ID: 32448160
[TBL] [Abstract][Full Text] [Related]
8. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
[TBL] [Abstract][Full Text] [Related]
9. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Pouessel D; Neuzillet Y; Mertens LS; van der Heijden MS; de Jong J; Sanders J; Peters D; Leroy K; Manceau A; Maille P; Soyeux P; Moktefi A; Semprez F; Vordos D; de la Taille A; Hurst CD; Tomlinson DC; Harnden P; Bostrom PJ; Mirtti T; Horenblas S; Loriot Y; Houédé N; Chevreau C; Beuzeboc P; Shariat SF; Sagalowsky AI; Ashfaq R; Burger M; Jewett MA; Zlotta AR; Broeks A; Bapat B; Knowles MA; Lotan Y; van der Kwast TH; Culine S; Allory Y; van Rhijn BW
Ann Oncol; 2016 Jul; 27(7):1311-6. PubMed ID: 27091807
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
11. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?
van Rhijn BWG; Mertens LS; Mayr R; Bostrom PJ; Real FX; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; van der Heijden MS; Jewett MAS; Marquez M; Stoehr R; Zlotta AR; Eckstein M; Soorojebally Y; Roshani H; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; Wullich B; van der Kwast TH; Malats N; Hartmann A; Allory Y; Zuiverloon TCM
Eur Urol; 2020 Nov; 78(5):682-687. PubMed ID: 32682615
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
14. TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.
Noel N; Couteau J; Maillet G; Gobet F; D'Aloisio F; Minier C; Pfister C
Anticancer Res; 2015 Sep; 35(9):4915-21. PubMed ID: 26254388
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
16. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
[TBL] [Abstract][Full Text] [Related]
17. Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis.
Traczyk-Borszynska M; Borkowska E; Jablonowski Z; Jedrzejczyk A; Pietrusinski M; Kaluzewski B; Sosnowski M; Borowiec M
Neoplasma; 2016; 63(6):952-960. PubMed ID: 27596295
[TBL] [Abstract][Full Text] [Related]
18. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
Knowles MA
World J Urol; 2007 Dec; 25(6):581-93. PubMed ID: 17912529
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis.
Liu X; Zhang W; Geng D; He J; Zhao Y; Yu L
Genet Mol Res; 2014 Feb; 13(1):1109-20. PubMed ID: 24634132
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
